We asked to ChatGPT what BIOMIMESYS technology can bring you to immuno-oncology

… And it is right ! “Biomimesys technology can bring several advantages in immuno-oncology by providing a more physiologically relevant 3D cell culture model for research. This technology uses a bioinspired extracellular matrix to create a three-dimensional environment that more closely resembles the natural cellular environment. In immuno-oncology, 2D cell Read more…

Development of personalized therapeutic targeting in lung cancer using 3D model with BIOMIMESYS® thanks to Plan France Relance and Region Hauts-de-France

It is with great pleasure that we announce the reinforcement of our collaboration about lung cancer between HCS Pharma and TARGET team of the OncoLille Institute (Team “Efficacy and resistance to anti-tumor targeted therapies”, CANTHER UMR9020, Lille, France). Initially supported by Région Hauts-de-France, this project has been initiated in spring Read more…

HCS Pharma will be present at next ELRIG event “Research and Innovation 2023 – Accelerating future DD” in Cambridge on March 29 and 30th

We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet with you and to present you our disruptive technology Read more…

Rania joins us to work on a Liver Biochip system

After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular carcinoma cell line) in Biochip, the project continue with Rania Chibani, who has joined us for a Read more…